When did VRTX join the S&P 500?

Vertex Pharmaceuticals joined the S&P 500 index on 2013-09-20.

What sector is VRTX in?

VRTX is in the Health Care sector, Biotechnology industry.

VRTX — Vertex Pharmaceuticals

Name: VRTX Institutional Holdings (13F) — 2026Q1
Creator: SEC EDGAR
License: https://www.sec.gov/data

Biotechnology · Health Care

Vertex Pharmaceuticals Incorporated is a global biotechnology company dedicated to discovering, developing, manufacturing and commercializing small molecule drugs for patients with serious diseases. The company focuses on developing and commercializing therapies for the treatment of cystic fibrosis, infectious diseases (including viral infections such as influenza and bacterial infections), autoimmune diseases (such as rheumatoid arthritis), cancer, inflammatory bowel disease and neurological disorders (including pain and multiple sclerosis).

Key Facts

Status	Active
Sector	Health Care
Industry	Biotechnology
Joined	2013-09-20
Tenure	12 yrs

S&P 500 Timeline

2013-09-20Joined S&P 500

Industry Peers

ABBV AMGN BIIB GILD INCY MRNA REGN

Sector Peers

A ABBV ABT ALGN AMGN BAX BDX BIIB BMY BSX

Institutional Holdings (13F)

1,752 institutions hold VRTX, totaling 738.1M shares ($125.5B) · As of 2026Q1

Rank	Institution	Shares	Value
1	VANGUARD CAPITAL MANAGEMENT LLC	39.3M	$14.8B
2	Capital World Investors	25.4M	$11.3B
3	BlackRock, Inc.	34.9M	$10.8B
4	Capital Research Global Investors	21.1M	$9.4B
5	STATE STREET CORP	13.6M	$5.3B
6	DZ BANK AG Deutsche Zentral Genossenschafts Bank, Frankfurt am Main	14.9M	$4.3B
7	BARCLAYS PLC	15.9M	$4.2B
8	MORGAN STANLEY	20.8M	$4.2B
9	JPMORGAN CHASE & CO	16.1M	$3.2B
10	GEODE CAPITAL MANAGEMENT, LLC	7.9M	$2.8B

View all holders →

Data source: Wikipedia · CC BY-SA 4.0 · SEC EDGAR 13F · Updated 2026-07-10